Inflammatory Bowel Disease and Gastrointestinal Inflammation
Takeda Development Center Americas Inc. funds research in ulcerative colitis, Crohn’s disease, chronic pouchitis, and complex perianal fistulas, with additional interest in pediatric and adult disease activity, mucosal healing, and remission outcomes. Its portfolio also includes studies in gastroesophageal reflux disease and erosive esophagitis, extending into pediatric gastrointestinal care.
- Ulcerative colitis
- Crohn’s disease
- Chronic pouchitis
- Perianal fistulizing disease
- GERD and erosive esophagitis
The sponsor’s gastrointestinal research spans both adult and pediatric populations, including refractory and moderate-to-severe inflammatory disease.
Immunology, Autoimmune Disease, and Dermatology
Takeda supports trials in plaque psoriasis, psoriatic arthritis, non-segmental vitiligo, and hidradenitis suppurativa, reflecting a strong focus on immune-mediated skin and joint disorders. Its immunology portfolio also includes primary immune thrombocytopenia, immune-mediated thrombotic thrombocytopenic purpura, and primary immunodeficiency diseases.
- Plaque psoriasis
- Psoriatic arthritis
- Vitiligo
- Hidradenitis suppurativa
- Immune thrombocytopenia and thrombotic thrombocytopenic purpura
Research in this area also covers secondary immunodeficiency and infection prophylaxis in immunocompromised patients.
Hematologic Malignancies and Myeloid Disorders
The sponsor funds studies in acute myeloid leukemia, Philadelphia chromosome-positive acute lymphoblastic leukemia, chronic myeloid leukemia, Hodgkin lymphoma, myelodysplastic syndromes, and myelofibrosis. Its hematology portfolio includes both malignant and bone marrow failure conditions, with attention to anemia and disease control in difficult-to-treat blood cancers.
- Acute myeloid leukemia
- Philadelphia chromosome-positive ALL
- Hodgkin lymphoma
- Myelodysplastic syndromes
- Myelofibrosis
Takeda’s oncology and hematology research also includes advanced solid tumours and metastatic cancer settings.
Neurology and Sleep Disorders
Takeda’s neuroscience research includes developmental and epileptic encephalopathies such as Dravet syndrome and Lennox-Gastaut syndrome, along with narcolepsy with cataplexy, narcolepsy without cataplexy, and multiple system atrophy. Additional work addresses attention-deficit/hyperactivity disorder and neurocognitive impairment in rare neurologic conditions.
- Dravet syndrome and Lennox-Gastaut syndrome
- Narcolepsy
- Multiple system atrophy
- ADHD
- Epileptic encephalopathies
The portfolio also includes pediatric neurologic research and long-term safety studies in rare central nervous system disorders.
Rare Diseases, Liver Disease, and Transplant-Related Infections
Takeda funds research in alpha-1 antitrypsin deficiency-associated liver disease, primary immunodeficiency diseases, Hunter syndrome, and cytomegalovirus infection in hematopoietic stem cell transplant and solid organ transplant recipients. Its rare disease work also includes severe von Willebrand disease, congenital or acquired bleeding disorders, and hepatic impairment.
- Alpha-1 antitrypsin deficiency-associated liver disease
- Primary immunodeficiency diseases
- Hunter syndrome
- Cytomegalovirus infection in transplant recipients
- Von Willebrand disease
These studies include both metabolic and inherited conditions, as well as infectious complications in highly vulnerable patient groups.
